✦ LIBER ✦

Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study

✍ Scribed by Ben A. van Hout; Lee Bowman; David J. Zelinger; Maarten L. Simoons

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

RM3: THE USE OF ABCIXIMAB FOR PERCUTANEO

✍ M Lage; B Barber; L Bowman; D Ball; M Bala 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

1001-7 The use of Abciximab during percu

✍ Piotr Kwiatkowski; Alessandro Manzoli; Costantino Caroselli; Fabrizio Imola; Ale 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 46 KB

The effects and mechanisms of high loadi

✍ Luo, Jun; Li, Jiang; Shen, Xiangqian; Hu, Xinqun; Fang, Zhenfei; Lv, Xiaolin; Zh 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 401 KB

Frequency and efficacy of glycoprotein I

✍ Karl K. Haase; Heiko Mahrholdt; Stephan Schröder; Andreas Baumbach; Martin Oberh 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 261 KB

Abciximab in the treatment of acute myoc

✍ Lambert F.M van den Merkhof; Felix Zijlstra; Hans Olsson; Lars Grip; Gerrit Veen 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 206 KB

PCV7 Cost-Effectiveness of Prasugrel Ver

✍ Mondragon, R.; Arrieta-Maturino, E.; Vargas-Valencia, J.J.; Martínez-Fonseca, J. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB